DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for Endometrial Serous Adenocarcinoma — screening already-approved drugs against its 47-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleEndometrial Serous Adenocarcinoma maps to a 47-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for endometrial serous adenocarcinoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
protein tyrosine phosphatase receptor type B (PTPRB) — PTPRB is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet tert-butoxycarbonyldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 2I4G · 1.65 Å · ligand N-(TERT-BUTOXYCARBONYL)-L-TYROSYL-N-METHYL-4-(SULFOAMINO)-L-PHENYLALANINAMIDE (UA1). Experimental structure, not a prediction.
What the evidence adds up to
In a 1986 series of 15 women with papillary serous adenocarcinoma of the endometrium, 8 cases (53.3%) were clinically understaged at laparotomy. Recurrent disease developed in 12 patients (80.0%), with ten of those recurrences arising within the abdomen. Eleven patients (73.3%) died of disease, and two of the four alive had been treated for a recurrence. The authors noted that intraoperative assessment for extrauterine spread was infrequently performed and called for determining appropriate adjuvant therapy.
A 2017 study of 93 patients with serous endometrial cancer reported median disease-free survival of 49.6 months and median overall survival of 32.2 months. Forty-three patients (46.2%) relapsed and 35 (37.6%) died. When the cohort was split by histology, 29 of 52 patients (55.8%) with pure serous cancer recurred compared with 14 of 41 (34.1%) with mixed serous histology. Twenty-five (48.1%) in the pure serous group died versus 10 (24.4%) in the mixed group. Mean disease-free survival was 59 months in the pure serous group versus 81 months in the mixed group, and mean overall survival was 73 versus 95 months. Histologic type was a significant prognostic factor for recurrence and overall survival in univariate analysis but not in multivariate analysis that included disease stage and age.
A 2006 review stated that uterine papillary serous cancer is an extremely aggressive cancer and that advanced disease is often unresponsive to conventional therapy. It noted that a potential precursor lesion, serous endometrial intraepithelial carcinoma, had been recognised as an early form of the disease and should be treated as such. Molecular markers identified included p53, HER2/neu, IL-6, kallikrein 6, and claudin-4, some of which might be susceptible to molecularly targeted therapy. A 2008 review confirmed that adjuvant therapy remains controversial and that no randomised trials on uterine papillary serous carcinoma exist. A 2011 review stated that uterine papillary serous carcinoma and clear cell carcinoma account for almost half of all relapses in endometrial cancer and that an individualised approach is required for recurrent disease.
What is still missing are randomised controlled trials specific to uterine papillary serous carcinoma, which have never been conducted. There is no consensus on the optimal adjuvant regimen, and the molecular targets identified have not yet translated into proven therapies that improve survival in this population. Patient stratification by histologic subtype (pure versus mixed) may matter, but the 2017 data show that histology was not an independent prognostic factor after adjusting for stage and age, leaving the role of tumour biology versus stage incompletely resolved.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Obstetrics and Gynecology · 1986 · 97 citations
Papillary Serous Adenocarcinoma of the Endometrium
AbstractThe clinical outcome of 15 women with papillary serous adenocarcinoma of the endometrium is presented. In 14 instances the diagnosis was made by uterine curettage. Eight cases (53.3%) were clinically understaged based on laparotomy findings. Intraoperative assessment for extrauterine spread of disease was infrequently performed. Recurrent disease developed in 12 patients (80.0%) with ten arising within the abdomen either alone or in conjunction with another site. Eleven patients (73.3%) have died of disease and two of the four alive have been treated for a recurrence. The need to determine appropriate adjuvant therapy for patients with this disease exists. A protocol for patient management is proposed.
AbstractEndometrial cancer is the most common gynecologic malignancy in the United States. The majority of women are diagnosed with early-stage, low-grade endometrioid tumors that are highly curable with primary surgery. Patients with more advanced and/or higher grade disease require multimodality therapy and have a higher risk for recurrence. Although uterine papillary serous carcinoma and clear cell carcinoma are diagnosed infrequently, they account for almost half of all relapses. As women with recurrent endometrial cancer constitute a heterogeneous group, an individualized approach is required. We review the treatment options of surgery, radiation, hormonal therapy, cytotoxic chemotherapy, and biological agents.
AbstractPURPOSE OF REVIEW: Uterine papillary serous cancer is an extremely aggressive cancer, the optimum management of which is still being determined. It is important to understand advances that have been made in 2005 regarding the molecular biology, diagnosis, and management of this deadly disease. RECENT FINDINGS: The main themes in the literature regarding uterine papillary serous cancer are that a potential precursor lesion, serous endometrial intraepithelial carcinoma, has been recognized as an early form of the disease. A variety of molecular biologically important markers have now been identified, including p53, HER2/neu, IL-6, kallikrein 6, and claudin-4, some of which may be susceptible to molecularly targeted therapy. Systematic surgical staging is necessary before additional therapy is recommended. Stage I uterine papillary serous cancer requires aggressive treatment, including surgery, chemotherapy, and radiation therapy for successful treatment. The most effective management of advanced stage disease remains to be resolved. SUMMARY: Serous endometrial intraepithelial carcinoma should be treated as a form of uterine papillary serous cancer. Multimodality therapy is required for the successful management of early stage uterine papillary serous cancer. Advanced disease is often unresponsive to conventional therapy. Molecularly targeted therapies are now being introduced into the management of this disease.
Current Opinion in Obstetrics & Gynecology · 2008 · 29 citations
Clinical aspects of uterine papillary serous carcinoma
AbstractPURPOSE OF REVIEW: We review the demographic and clinicopathologic characteristics, and prognosis of women diagnosed with uterine papillary serous carcinoma, with a focus on clinical management. RECENT FINDINGS: Pathologic evaluation of postmenopausal bleeding is preferred for patients who fit the profile of a high-risk endometrial cancer such as uterine papillary serous carcinoma. Women diagnosed with endometrial cancer who fit this profile and all women with uterine papillary serous carcinoma should undergo comprehensive surgical staging and aggressive cytoreduction of extrauterine disease. Adjuvant therapy remains controversial. Several recent investigations reported on the potential benefit of adjuvant chemotherapy, with many recommending additional loco-regional radiation. SUMMARY: Despite the lack of randomized trials on uterine papillary serous carcinoma, several recent reports have provided insight into the diagnosis, surgical management, and adjuvant treatment of this high-risk endometrial cancer.
Journal of the National Comprehensive Cancer Network · 2006 · 14 citations
Uterine Cancers Clinical Practice Guidelines
AbstractAdenocarcinoma of the endometrium is the most common malignancy of the female genital tract in the United States. Many physicians believe that adenocarcinoma of the endometrium is a relatively benign disease because of the early symptoms of irregular vaginal bleeding in this predominantly postmenopausal patient population, the often-localized nature of the disease, and the generally high survival rate. However, the estimated number of deaths from endometrial cancer continues to increase, indicating the need for a critical reassessment of the guidelines for managing endometrial cancer. Physicians must identify high-risk patients and tailor treatment appropriately to provide the best opportunity for long-term survival. For the most recent version of the guidelines, please visit NCCN.org
Journal of the Turkish-German Gynecological Association · 2017 · 4 citations · open access
Clinicopathologic and survival results in serous endometrium carcinoma and subgroup analysis for mixed serous and pure serous histology
AbstractOBJECTIVE: To review the clinicopathologic and survival outcomes of patients with serous endometrial cancer (EC) and to investigate subgroup analysis based on pure serous and mixed serous EC subtypes. MATERIAL AND METHODS: Patients who underwent EC surgery between 2002 and 2014 and who were reported as serous EC were enrolled in the study. All patients were diagnosed as having serous EC or mixed serous EC with serous component higher than 10% based on the postoperative pathology report. RESULTS: A total of 93 patients were analyzed. The median disease-free and overall survival (OS) durations were 49.6 and 32.2 months, respectively. Forty-three patients (46.2%) relapsed and 35 patients (37.6%) died. The histologic type was pure serous EC in 52 (55.9%) and mixed EC in 41 (44.9%) patients. There was no statistical difference between the pure serous and mixed serous groups in terms of age, International Federation of Gynecology and Obstetrics stage, lymphadenectomy, lymph node metastasis or adjuvant therapy combinations. Twenty-nine (55.8%) patients in the pure serous group and 14 (34.1%) in the mixed serous group hade recurrence (p=0.038). Twenty-five (48.1%) patients in the pure serous group and 10 (24.4%) in the mixed serous group died (p=0.034). In the pure serous group, the mean disease-free and OS durations were shorter than in the mixed serous group (59 vs. 81 months and 73 vs. 95 months, log-rank p=0.055 and 0.041, respectively). Histologic type was a significant prognostic factor on recurrence and OS in the univariate analysis (Hazard ratio: 2.404, 95% Confidence interval: 1.01-5.71; 2.027, respectively), but not in the multivariate analysis, which included disease stage and age of the patients. CONCLUSION: Compared with pure serous and mixed serous endometrium cancer groups, primary surgical treatments, clinicopathologic features and adjuvant treatments were similar, but there was a survival difference. Patients with pure serous cancer had a worse prognosis. However histology was not an independent factor for survival.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
